SCHEMBL21274752

SCHEMBL21274752

CC(C)(C)OC(=O)N1[C@H](CCCO)CCC1(C)C

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SPHK1 Q9NYA1 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ CYP4F2 P78329 1/20 0.34
▸ CYP4A11 Q02928 1/20 0.34
▸ DDB1 Q16531 2/20 0.33
▸ CRBN Q96SW2 2/20 0.33
▸ CTSK P43235 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.32
▸ GPR119 Q8TDV5 4/20 0.32
▸ HPGD P15428 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21244705 1.00 SPHK1 (0.35) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL21288270 0.89 SPHK1 (0.42) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL21275014 0.88 SPHK1 (0.34) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL21245137 0.88 SPHK1 (0.34) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL21274727 0.86 SPHK1 (0.34) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL21244975 0.86 SPHK1 (0.34) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL19959327 0.85 NR1H2 (0.41) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL19637550 0.85 NR1H2 (0.41) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL13606646 0.85 NR1H2 (0.41) SPHK1NR1H2CHRM2CHRM1CHRM3
SCHEMBL21274856 0.84 CHRM2 (0.35) SPHK1NR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752510-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM Vertex Pharmaceuticals Incorporated (US) 2020-12-23 — — EP disclosed
WO-2019161078-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-08-22 — — WO disclosed
Send feedback